Efficacy and Safety of Sintilimab and Apatinib Combined Chemotherapy in Breast Cancer
Status:
Recruiting
Trial end date:
2023-01-31
Target enrollment:
Participant gender:
Summary
1. The efficacy and safety of immunotherapy and antiangiotherapy in combination with
chemotherapy in neoadjuvant therapy for triple-negative breast cancer (TNBC) were
determined by the addition of sintilimab and apatinib to neoadjuvant chemotherapy
2. To clarify the breast-conserving rate, toxicity, difference in pathologic complete
response (pCR) rate of patients with PD-L1 (+) and PD-L1 (-) after neoadjuvant treatment
of TNBC with immunotherapy and anti-vascular therapy combined with chemotherapy and the
relationship between pCR rate of immunomodulated type (IM) and non-immunomodulated type
patients in "Fudan classification".
3. Through post-treatment efficacy evaluation and safety analysis, we provide new treatment
strategies for TNBC patients, increase the pCR rate of TNBC patients, and ultimately
improve the long-term survival of patients.